Search Results
Sep 04, 2026, 16:00 ET Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
www.inhibrx.com.About INBRX-106INBRX-106 is a hexavalent agonist targeting OX40 (CD134), a costimulatory receptor on T-cells. Utilizing Inhibrx's proprietary single-domain antibody (sdAb) platform, INBRX-106 is designed to achieve the
More news about: Inhibrx Biosciences, Inc.
Sep 04, 2026, 09:21 ET AICost.ai Expands Its Independent AI Cost, Policy and Governance Decision-Intelligence Platform for the Agentic, Multi-Model Enterprise
AICost MCP beta, exposing the full engine fleet and reusable decision chains to AI agents, coding assistants, gateways and CI/CD pipelines, at [email protected].
More news about: CloudIntelligence.ai llc
Sep 03, 2026, 20:06 ET Lucid bringt mit Unterstützung von Emil Frey France seine preisgekrönten Fahrzeuge nach Frankreich
https://assets.lucidmotors.com/transfer/eb292e5d7f3d7a07240cd572e54c46cb454bab0f2124521ee090cb335dde963a Informationen zur Lucid Group Die Lucid Group, Inc. (NASDAQ:
More news about: Lucid Motors
Sep 03, 2026, 19:05 ET BEYONCÉ MARKS HER BIRTHDAY WITH THE RELEASE OF A REMASTERED DELUXE "B'DAY" ALBUM HER COMING-OF-AGE MASTERPIECE IS AMPLIFIED WITH UPGRADED VISUALS, SURPRISE NEW TRACKS, AND SPANISH LANGUAGE SONGS, INCLUDING COLLABORATIONS WITH MALUMA AND THE LATE SELENA
included on B'DAY in 2006.B'DAY (20th Anniversary Edition), is available in standard and deluxe volumes on vinyl and CD, as well as a deluxe digital offering. B'DAY 20th Anniversary Edition - Standard Vinyl is a limited edition 180G 2LP
More news about: Parkwood Entertainment
Sep 03, 2026, 16:46 ET PROJECT HEALTHY MINDS AND HARVARD BUSINESS SCHOOL RESEARCHERS TO EXPAND THE EVIDENCE BASE AROUND WORKFORCE MENTAL HEALTH
and AI Enablement Officer of ServiceNow, and Stephanie Kramer, Chief Human Resources Officer of L'Oréal North America. Ryan W. Buell, CD Spangler Professor of Business Administration at Harvard Business School serves as an academic collaborator with the Coalition, helping to shape
More news about: Project Healthy Minds
Sep 03, 2026, 15:16 ET Lucid va commercialiser ses véhicules primés en France avec le soutien d'Emil Frey France
https://assets.lucidmotors.com/transfer/eb292e5d7f3d7a07240cd572e54c46cb454bab0f2124521ee090cb335dde963a À propos de Lucid Group Lucid Group, Inc. (NASDAQ : LCID)
More news about: Lucid Motors
Sep 03, 2026, 15:05 ET Lucid llevará vehículos galardonados a Francia con el apoyo de Emil Frey France
https://assets.lucidmotors.com/transfer/eb292e5d7f3d7a07240cd572e54c46cb454bab0f2124521ee090cb335dde963a Acerca de Lucid GroupLucid Group, Inc. (NASDAQ: LCID) es una empresa tecnológica
More news about: Lucid Motors
Sep 03, 2026, 11:16 ET Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application
first-in-class CD19xBCMAxCD3 tri-specific T-cell engager (TCE) being developed for a broad range of B cell–mediated autoimmune diseases. The novel, IgG-like tri-specific antibody binds CD19 and BCMA to reach a wide spectrum of B-cell populations, including plasma cells, while engaging CD3 through a proprietary
More news about: Kali Therapeutics
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM).
More news about: AbbVie
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
(ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Sep 03, 2026, 04:00 ET Lucid To Bring Award-Winning Vehicles to France with Emil Frey France's support
https://assets.lucidmotors.com/transfer/eb292e5d7f3d7a07240cd572e54c46cb454bab0f2124521ee090cb335dde963a About Lucid Group Lucid Group, Inc. (NASDAQ: LCID) is a technology
More news about: Lucid Motors
Sep 02, 2026, 12:51 ET empirik.ai emerges from stealth with $21 Million to build the AI Agent for Infrastructure Change
the AI agent for infrastructure change. By continuously modeling the complete application environment, across cloud, on-prem, Kubernetes, VMs, IAM, CI/CD, and SaaS, empirik.ai enables engineering teams to understand intent behind a change, compute its blast radius, and execute changes safely within governed
More news about: empirik.ai
Sep 02, 2026, 12:49 ET Simcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660
d'engagement CD3 à des domaines de liaison ciblant les deux antigènes des lymphocytes B, le CD79a et le CD19, afin d'induire une cytotoxicité puissante à médiation lymphocytaire T tout en limitant la libération de cytokines. Grâce à son approche innovante de double ciblage du CD79a et du CD19, qui pourrait
More news about: Simcere
Sep 02, 2026, 08:30 ET Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
tumors were associated with shorter overall survival than PRMT5-high/MTAP-non-deleted tumors.PRMT5-high/MTAP-deleted tumors exhibited fewer CD8+ T-cells and other adaptive immune cells, suggesting a less favorable immune microenvironment.Prevalence of Immunotherapy (IO) Biomarkers,
More news about: Caris Life Sciences
Sep 02, 2026, 04:02 ET Simcere Zaiming schließt exklusive Lizenzvereinbarung mit Roche über die weltweite Entwicklung von SIM0660
einen CD3-bindenden Arm mit Bindungsdomänen, die auf die beiden B-Zell-Antigene CD79a und CD19 abzielen, um eine starke T-Zell-vermittelte Zytotoxizität zu induzieren und gleichzeitig die Zytokinfreisetzung zu begrenzen. Mit seinem potenziell erstklassigen Dual-Targeting-Ansatz gegen CD79a und CD19 ist
More news about: Simcere
Sep 02, 2026, 04:00 ET Simcere Zaiming sluit exclusieve licentieovereenkomst met Roche voor wereldwijde ontwikkeling van SIM0660
een CD3-engagerende arm met bindingsdomeinen die zich richten op de twee B-celantigenen CD79a en CD19 om krachtige T-celgemedieerde cytotoxiciteit te induceren en tegelijkertijd de vrijlating van cytokines te beperken. Met zijn potentieel baanbrekende first-in-class benadering gericht op zowel CD79a als
More news about: Simcere
Sep 02, 2026, 02:04 ET Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
window.Evotec's BiTco platform is based on a proprietary, non-blocking CD2 antibody designed to provide an additional costimulatory signal to T cells, enhancing their activity and persistence within the tumor microenvironment. The antibody targets a unique CD2 epitope while preserving its natural interactions, enabling
More news about: Evotec SE
Sep 01, 2026, 08:38 ET Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release. With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide
More news about: Simcere
Sep 01, 2026, 08:28 ET Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release. With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide
More news about: Simcere
Sep 01, 2026, 08:00 ET RateZip Launches Live US Bank Rate and Mortgage Rate App in ChatGPT
RateZip Deposit/Mortgage Rates in the ChatGPT app directory: live US savings, CD, mortgage, and HELOC rates with a source and timestamp on every number.NEW YORK, Sept. 1, 2026 /PRNewswire/ -- RateZip, an independent
More news about: RateZip
Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.[4] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile
More news about: RedHill Biopharma Ltd.
Sep 01, 2026, 04:00 ET Zyklus im Wiener Musikverein widmet sich der Musik „Jenseits vom tanzenden Wien"
gegründete Auner Quartett gewann 2018 den Eugène-Ysaÿe-Wettbewerb in Liège und war 2020/21 NASOM-Kulturbotschafter Österreichs. Seine CD „Versinkende Sonne" wurde zur Ö1-CD des Jahres 2022 gewählt. Primarius Daniel Auner spielt eine Guadagnini-Violine, eine Dauerleihgabe der Oesterreichischen Nationalbank.
More news about: Kammermusikforum Wien
Sep 01, 2026, 04:00 ET Vienne redécouvre les compositeurs que le nazisme avait fait taire
remporté en 2018 le Concours Eugène Ysaÿe à Liège et fut ambassadeur culturel de l'Autriche (NASOM) en 2020/21. Son disque « Versinkende Sonne » fut élu « CD de l'année Ö1 2022 ».Photo : https://mma.prnewswire.com/media/3008705/Auner_Quartett.jpgDates
More news about: Kammermusikforum Wien
Aug 31, 2026, 10:30 ET Xenograft Model Selection and Standardization Across CDX, PDX, Humanized, and Organoid-Derived Models in Preclinical Cancer Research
determines what those studies can conclude: hu-PBMC models reconstitute T cells rapidly but are bounded by graft-versus-host disease within weeks, hu-CD34 models support longer studies with incomplete myeloid reconstitution, and autologous humanized PDX eliminates MHC mismatch between immune and tumor
More news about: Altogen Labs
Aug 31, 2026, 08:30 ET Three Scalp Conditions May Point to a Single Syndrome, New Study Finds
around the upper hair follicle. Samples from AKN, DCS and normal-looking scalp shared a similar immune-cell pattern, with more CD4-positive than CD8-positive T cells and prominent CD117-positive mast cells.One patient's father showed a similar but unconfirmed clinical pattern: a nape plaque suggestive
More news about: Dr. U Hair and Skin Clinic